Neuroprotective efficacy of the peroxisome proliferator-activated receptor δ-selective agonists in vitro and in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 3, 2007, Pages 1087-1096

  Iwashita, Akinori ^a   Muramatsu, Yuko ^a   Yamazaki, Takao ^a   Muramoto, Masakazu ^a   Kita, Yasuhiro ^a   Yamazaki, Shunji ^a   Mihara, Kayoko ^a   Moriguchi, Akira ^a   Matsuoka, Nobuya ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; CASPASE 3; DOPAMINE; HOMOVANILLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; STAUROSPORINE; THAPSIGARGIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN ISCHEMIA; BRAIN PERFUSION; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; CYTOTOXICITY; DOPAMINE BRAIN LEVEL; DRUG EFFICACY; ENZYME INHIBITION; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; METABOLITE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REPERFUSION; TIME;

ACETIC ACIDS; ANIMALS; BRAIN; BRAIN ISCHEMIA; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOPAMINE; GENES, REPORTER; HUMANS; LIGANDS; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHENOLS; PPAR DELTA; RATS; RATS, WISTAR; SUBSTRATE SPECIFICITY; THIAZOLES;

EID: 33847169097     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.115758     Document Type: Article

References (37)

1. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, and Evans RM (2002) Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 99:303-308.
2. Bastie C, Holst D, Gaillard D, Jehl-Pietri C, and Grimaldi PA (1999) Expression of peroxisome proliferator-activated receptor PPARδ promotes induction of PPARγ and adipocyte differentiation in 3T3C2 fibroblasts. J Biol Chem 274:21920-21925.
3. Berg D, Holzmann C, and Riess O (2002) 14-3-3 proteins in the nervous system. Nat Rev Neurosci 4:752-762.
4. Bernardo A, Levi G, and Minghetti L (2000) Role of the peroxisome proliferator-activated receptor-γ (PPAR-γ) and its natural ligand 15-deoxy-12,14-prostaglandin J2 in the regulation of microglial functions. Eur J Neurosci 12:2215-2223.
5. Besson VC, Chen XR, Plotkine M, and Marchand-Verrecchia C (2005) Fenofibrate, a peroxisome proliferator-activated receptor agonist, exerts neuroprotective effects in traumatic brain injury. Neurosci Lett 388:7-12.
6. Braissant O, Foufelle F, Scotto C, Dauca M, and Wahli W (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 137:354-366.
7. Breidert T, Callebert J, Heneka T, Landreth G, Launay JM, and Hirsch EC (2002) Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 82:615-624.
8. 2) protects rat cortical neurons in culture against hypoxia/reoxygenation and glutamate-induced injury. Neurosci Lett 160:106-108.
9. Cristiano L, Bernardo A, and Ceru MP (2001) Peroxisome proliferator-activated receptors (PPARs) and peroxisomes in rat cortical and cerebellar astrocytes. J Neurocytol 30:671-683.
10. Dehmer T, Heneka MT, Sastre M, Dichgans J, and Schulz JB (2004) Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation. J Neurochem 88:494-501.
11. Deplanque D, Gele P, Petrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, et al. (2003) Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 23:6264-6271.
12. Durkin JP, Tremblay R, Chakravarthy B, Mealing G, Morley P, Small D, and Song D (1997) Evidence that the early loss of membrane protein kinase C is a necessary step in the excitatory amino acid-induced death of primary cortical neurons. J Neurochem 68:1400-1412.
13. Hao CM, Redha R, Morrow J, and Breyer MD (2002) Peroxisome proliferatoractivated receptor δ activation promotes cell survival following hypertonic stress. J Biol Chem 277:21341-21345.
14. Imai Y, Soda M, and Takahashi R (2000) Parkin suppresses unfolded protein stressinduced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 275:35661-35664.
15. Iwashita A, Maemoto T, Nakada H, Shima I, Matsuoka N, and Hisajima H (2003) A novel potent radical scavenger, 8-(4-fluorophenyl)-2-((2e)-3- phenyl-2-propenoyl)-1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine (FR210575), prevents neuronal cell death in cultured primary neurons and attenuates brain injury after focal ischemia in rats. J Pharmacol Exp Ther 307:961-968.
16. Iwashita A, Tojo N, Matsuura S, Yamazaki S, Kamijo K, Ishida J, Yamamoto H, Hattori K, Matsuoka N, and Mutoh S (2004a) A novel and potent poly(ADPribose) polymerase-1 inhibitor, 5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)- pyridinyl)propyl]-4(3H)-quinazolinone (FR247304), attenuates neuronal damage in vitro and in vivo models of cerebral ischemia. J Pharmacol Exp Ther 310:425-436.
17. Iwashita A, Yamazaki S, Mihara K, Hattori K, Yamamoto H, Ishida J, Matsuoka N, and Mutoh S (2004b) Neuroprotective effects of novel poly(ADP-ribose) polymerase-1 inhibitor, 2-{3-[4-(4-chlorophenyl)-1-piperazinyl] propyl}-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Pharmacol Exp Ther 309:1067-1078.
18. Katayama T, Imaizumi K, Sato N, Miyoshi K, Kudo T, Hitomi J, Morihara T, Yoneda T, Gomi F, Mori Y, et al. (1999) Presenilin-1 mutations downregulate the signaling pathway of the unfolded-protein response. Nat Cell Biol 1:479-485.
19. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, and Evans RM (1994) Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91:7355-7359.
20. Kojo H, Fukagawa M, Tajima K, Suzuki A, Fujimura T, Aramori I, Hayashi K, and Nishimura S (2003) Evaluation of human peroxisome proliferator-activated receptor (PPAR) subtype selectivity of a variety of anti-inflammatory drugs based on a novel assay for PPARα(β). J Pharmacol Sci 93:347-355.
21. Leibowitz MD, Fievet C, Hennuyer N, Peinado-J, Duez H, Berger J, Cullinan CA, Sparrow CP, Baffic J, Berger GD, et al. (2000) Activation of PPARδ alters lipid metabolism in db/db mice. FEBS Lett 473:333-336.
22. Lemberger T, Braissant O, Juge-Aubry C, Keller H, Saladin R, Steals B, Auwerx J, Burger A, Meier CA, and Wahli W (1996) PPAR tissue distribution and interactions with other hormone-signaling pathways. Ann NY Acad Sci 804:231-251.
23. Letavernier E, Perez J, Joye E, Bellocq A, Fouqueray B, Haymann JP, Heudes D, Wahli W, Desvergne B, and Baud L (2005) Peroxisome proliferator-activated receptor β/δ exerts a strong protection from ischemic acute renal failure. J Am Soc Nephrol 16:2395-2402.
24. Liou JY, Lee S, Ghelani D, Matijevic-Aleksic, and Wu KK (2006) Protection of endotherial survival by peroxisome proliferator-activated receptor-α mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol 26:1481-1487.
25. Lo EH, Bosque-Hamilton P, and Meng W (1998) Inhibition of poly(ADP-ribose) polymerase: reduction of ischemic injury and attenuation of N-methyl-D-aspartate-induced neurotransmitter dysregulation. Stroke 29:830-836.
26. Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, Graham SH, and Chen J (2006) Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. J Neurochem 97:435-448.
27. Matsuura H, Adachi H, Smart RC, Xu X, Arata J, and Jetten AM (1999) Correlation between expression of peroxisome proliferator-activated receptor and squamous differentiation in epidermal and tracheobronchial epithelial cells. Mol Cell Endocrinol 147:85-92.
28. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, et al. (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306-5311.
29. Paschen W (1996) Disturbances of calcium homeostasis within the endoplasmic reticulum may contribute to the development of ischemic-cell damage. Med Hypotheses 47:283-288.
30. Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, and Gonzalez FJ (2000) Growth, adipose, brain, and skin alterations resulting from targeted distribution of the mouse peroxisome proliferator-activated receptor β(δ). Mol Cell Biol 20:5119-5128.
31. Pelton P (2006) GW-501516 GlaxoSmithKline/ligand. Curr Opin Investig Drugs 7:360-370.
32. Schoonjans K, Staels B, and Auwerx J (1996) The peroxisome proliferator activated receptor (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302:93-109.
33. Shimazu T, Inoue I, Araki N, Asano Y, Sawada M, Furuya D, Nagoya H, and Greenberg JH (2005) A peroxisome proliferator-activated receptor-γ agonist reduces infarct size in transient but not in permanent ischemia. Stroke 36:353-359.
34. Smith SA, Monteith GR, Robinson JA, Venkata NG, May FJ, and Roberts-Thomson SJ (2004) Effect of the peroxisome proliferator-activated receptor β activator GW0742 in rat cultured cerebellar granule neurons. J Neurosci Res 77:240-249.
35. Woods JW, Tanen M, Figueroa DJ, Biswas C, Zycband E, Moller DE, Austin CP, and Berger JP (2003) Localization of PPARγ in murine central nervous system: expression in oligodendrocytes and neurons. Brain Res 975:10-21.
36. Xing G, Zhang L, Zhang L, Heynen T, Yoshikawa T, Smith M, Weiss S, and Detera-Wadleigh S (1995) Rat PPAR δ contains a CGG triplet repeat and is prominently expressed in the thalamic nuclei. Biochem Biophys Res Commun 217:1015-1025.
37. Zhao Y, Patzer A, Herdegen T, Gohlke P, and Culman J (2006) Activation of cerebral peroxisome proliferator-activated receptor gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal ischemia in rats. FASEB J 20:1162-1175.